tegafur has been researched along with Esophageal Neoplasms in 148 studies
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "With a view to improving treatment response and the quality of life of cancer patients, this study investigated the clinical efficacy of combining lentinan, a flavonoid compound with antitumor abilities, with traditional chemotherapy in individuals with esophageal carcinoma (EC), with a particular focus on its effect on immune function." | 9.16 | Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. ( Bi, Z; Gu, XM; Wang, JL; Zou, JW, 2012) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 9.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 7.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "This study investigated the clinical efficacy and toxicity of the combination chemotherapy using S-1 plus irinotecan for esophageal adenocarcinoma." | 7.78 | A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma. ( Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y, 2012) |
| "Apatinib has shown promising outcomes in treatment with various solid tumors." | 6.94 | Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 6.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| "4%) and renal adverse events (all grades: CS, 18." | 6.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "Apatinib has been proven to significantly prolong the survival of the patients with advanced chemotherapy-refractory gastric cancer." | 6.66 | S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. ( Liu, D; Yu, GM; Zhang, C; Zhang, M, 2020) |
| " We performed this retrospective study to evaluate the efficacy and safety of apatinib combined with S-1/capecitabine as the oral maintenance therapy for these patients." | 5.62 | Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. ( Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021) |
| "In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC)." | 5.34 | An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. ( Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S, 2020) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 5.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "With a view to improving treatment response and the quality of life of cancer patients, this study investigated the clinical efficacy of combining lentinan, a flavonoid compound with antitumor abilities, with traditional chemotherapy in individuals with esophageal carcinoma (EC), with a particular focus on its effect on immune function." | 5.16 | Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. ( Bi, Z; Gu, XM; Wang, JL; Zou, JW, 2012) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 5.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received UFT/leucovorin, carboplatin, and paclitaxel with RT (1." | 5.13 | A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma. ( Bendell, JC; Cohen, DP; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Lockhart, AC; Petros, WP; Truax, R; Willett, CG, 2008) |
| "Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)." | 3.91 | S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019) |
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 3.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "This study investigated the clinical efficacy and toxicity of the combination chemotherapy using S-1 plus irinotecan for esophageal adenocarcinoma." | 3.78 | A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma. ( Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y, 2012) |
| "We treated a patient with inoperable advanced gastric cancer and malignant ascites by combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)." | 3.72 | [A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)]. ( Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T, 2003) |
| "Apatinib has shown promising outcomes in treatment with various solid tumors." | 2.94 | Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| " Grade ≥3 treatment-related adverse events (TRAEs) were reported by 57." | 2.94 | Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. ( Amagai, K; Azuma, M; Baba, H; Esaki, T; Han, SR; Hara, H; Hosaka, H; Kawakami, H; Kawazoe, A; Komatsu, Y; Machida, N; Negoro, Y; Nishina, T; Omuro, Y; Oshima, T; Shiratori, S; Shitara, K; Tsuda, M; Yamaguchi, K; Yasui, H; Yoshida, K, 2020) |
| "The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established." | 2.90 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. ( Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S, 2019) |
| "The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study." | 2.90 | A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019) |
| "Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy." | 2.90 | Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. ( Cai, H; Du, C; Fang, Y; Huang, D; Huang, H; Jin, J; Li, G; Liu, X; Long, Z; Lu, Q; Ma, M; Sheng, W; Wang, Y; Wu, J; Xie, L; Yin, J; Zhang, Z; Zhao, G; Zhou, M; Zhou, Y; Zhu, H; Zhu, J; Zhu, X, 2019) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 2.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| "Thoracic esophageal cancer patients with clinical stage II/III disease, excluding T4, were eligible." | 2.80 | Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). ( Boku, N; Fuse, N; Kanato, K; Kato, K; Mizusawa, J; Muro, K; Nihei, K; Ohtsu, A; Sato, A; Tahara, M; Takaishi, H; Yamazaki, K, 2015) |
| "Patients with stage II, III, or IVA esophageal cancer were randomly allocated to either 2 cycles of ICT (oxaliplatin 130 mg/m(2) on day 1 and S1 at 40 mg/m(2) twice daily on days 1-14, every 3 weeks) followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m(2) on days 1 and 21 and S1 30 mg/m(2) twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A), or the same CCRT followed by esophagectomy without ICT (arm B)." | 2.80 | Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. ( Cho, KJ; Jang, G; Jung, HY; Kim, HR; Kim, JH; Kim, JY; Kim, SB; Kim, YH; Lee, GH; Ryu, JS; Song, HY; Yoon, DH, 2015) |
| "Eligible patients had stage IIA-IVA esophageal cancer." | 2.79 | A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. ( Bae, MK; Cha, J; Chang, H; Cho, BC; Chung, H; Hur, J; Kim, CB; Kim, DJ; Kim, HI; Kim, HR; Kim, JH; Lee, CG; Lee, CY; Lee, H; Lee, JG; Lee, SK; Lee, YC; Park, JC; Shin, SK, 2014) |
| "4%) and renal adverse events (all grades: CS, 18." | 2.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "Adjuvant chemotherapy trial of TS-1 for gastric cancer study demonstrated that postoperative S-1 chemotherapy for 1 year improved overall survival of locally advanced gastric cancer (LAGC) patients." | 2.78 | A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH, 2013) |
| "How best to manage advanced esophageal cancer remains unresolved, especially in palliative care." | 2.73 | Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. ( Ahn, JS; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Lee, SR; Nam, TK; Shim, HJ; Yang, DH, 2008) |
| " We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy." | 2.72 | [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. ( Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006) |
| "Chemoradiotherapy combined with 5-fluorouracil and cisplatin have been effective for the treatment of advanced esophageal cancer, but superior treatments are needed." | 2.72 | [Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer]. ( Iwase, H, 2006) |
| "Ten patients with resectable esophageal cancer were enrolled." | 2.71 | Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. ( Beauchamp, RD; Berlin, J; Blanke, CD; Caillouette, C; Chakravarthy, B; Choy, H; Leach, S; Roberts, J; Shyr, Y; Tarpley, J; Tedesco, KL; Teng, M; Wyman, K, 2005) |
| "No effective treatment for advanced esophageal cancer extending to adjacent organs or associated with distant metastasis is known." | 2.71 | Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy. ( Horiuchi, Y; Indo, T; Iwase, H; Iyo, T; Kaida, S; Kato, E; Kusugami, K; Nakamura, M; Nakarai, K; Shimada, M, 2003) |
| " UFT and other oral 5FU dosing strategies make promising components of combination chemotherapy, deserving further, randomised evaluation." | 2.69 | Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer. ( Cresswell, H; Dent, JT; Papamichael, D; Seymour, MT; Slevin, ML; Wilson, G, 1999) |
| "Apatinib has been proven to significantly prolong the survival of the patients with advanced chemotherapy-refractory gastric cancer." | 2.66 | S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. ( Liu, D; Yu, GM; Zhang, C; Zhang, M, 2020) |
| " Thereafter, salvage minimally invasive Ivor-Lewis esophagectomy and 2-field lymph node dissection was performed, followed by oral apatinib plus S-1 at the prior dosage for 6 months." | 2.66 | S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature. ( Gong, LB; Wu, W; Yu, GM; Zhang, C; Zhang, M, 2020) |
| " However, radiotherapy combined with 5-FU/cisplatin often delivers severe toxicity to patients." | 2.58 | Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol. ( Liu, F; Song, Y; Wang, W; Xing, D, 2018) |
| "A 65-year-old woman ofesophageal cancer received preoperative chemotherapy, and developed EFR before operation." | 2.55 | [Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report]. ( Fujiwara, T; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Noma, K; Shirakawa, Y; Tanabe, S, 2017) |
| "In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer." | 2.52 | [Adjuvant treatment for esophagogastric junction cancer]. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| "Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial." | 2.46 | Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma. ( Gao, XS; Li, XY; Liu, CX, 2010) |
| " Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6." | 2.44 | Medical treatment for advanced gastroesophageal adenocarcinoma. ( Ajani, JA; Cen, P, 2007) |
| " We performed this retrospective study to evaluate the efficacy and safety of apatinib combined with S-1/capecitabine as the oral maintenance therapy for these patients." | 1.62 | Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. ( Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021) |
| " The main adverse events (AEs) of anlotinib combined with S-1 were fatigue (58." | 1.62 | Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy. ( Cai, J; Liu, A; Luo, Y; Zhou, S, 2021) |
| " Adverse events related to S-1 treatment were mostly grade 1 or 2 while reported grade 3-4 serious adverse events related to S-1 occurred in 12 patients and were most often grade 3 neutropenia (n = 4, 3." | 1.51 | S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. ( Venerito, M, 2019) |
| "He was preoperatively diagnosed with esophageal cancer, T3N2M0, Stage III ." | 1.46 | [Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer]. ( Fujiwara, T; Kagawa, S; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Nishizaki, M; Noma, K; Shirakawa, Y; Tanabe, S, 2017) |
| "Patients with early and advanced esophageal cancer and relapsed esophageal cancer after radical surgery were included." | 1.43 | Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer. ( Haga, A; Kiritoshi, T; Nakagawa, K; Ohtomo, K; Okuma, K; Takenaka, R; Yamashita, H, 2016) |
| "Patients with esophageal cancer treated with esophagectomy by the same surgeon between 2004 and 2011 were reviewed." | 1.42 | Preoperative chemoradiation therapy decreases the number of lymph nodes resected during esophagectomy. ( Batirel, HF; Bilgi, Z; Celikel, CA; Ermerak, NO; Issaka, A; Kara, VH, 2015) |
| "The patient died from recurrence of gastric cancer 69 months after completion of the initial chemotherapy and 2 months after the stent insertion." | 1.40 | [Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy]. ( Ishiyama, S; Iwasaki, Y; Maeda, Y; Natsume, S; Oohinata, R; Takahashi, K; Yajima, K; Yuu, K, 2014) |
| "We report a case of advanced esophageal cancer with a funnel chest deformity that was very difficult to reconstruct after thoracoscopy-assisted resection." | 1.39 | [A case of esophageal cancer with a funnel chest]. ( Akami, T; Matsumura, A; Matsuyama, T; Mugitani, T; Nishibeppu, K; Ogino, S; Shimode, Y; Takemura, M, 2013) |
| "It may be useful for esophageal squamous cell carcinoma (ESCC); however, there are insufficient data." | 1.39 | S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. ( Akutsu, Y; Hanaoka, T; Hoshino, I; Kono, T; Matsubara, H; Narushima, K; Qin, W; Semba, Y; Tochigi, T; Uesato, M, 2013) |
| "Advanced gastric cancer was found at the fundus of the stomach, and severe dysplasia was found at the lower esophagus." | 1.38 | [A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy]. ( Hosaka, S; Inada, K; Kawamoto, S; Kikutake, T; Maeno, H; Nagao, S; Okubo, S; Umemoto, S; Yoshida, T, 2012) |
| "Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck." | 1.38 | Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ( Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012) |
| "Patients with T4 esophageal cancer generally have poor prognosis." | 1.37 | [A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Yoneda, M, 2011) |
| "She was diagnosed as a type 3 gastric cancer (por/tub2) of the esophagogastric junction by gastrointestinal endoscopy in November 2010." | 1.37 | [A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy]. ( Ebisui, C; Ide, Y; Kinuta, M; Momozane, T; Mukai, R; Murakami, M; Murata, K; Nagase, H; Nishigaki, T; Okada, K; Owada, Y; Tamai, M; Yanagisawa, T; Yokouchi, H, 2011) |
| "We report a case of early-stage mucosal esophageal cancer, showing a complete response to S-1 and cis-diamminedichloplatinum (CDDP)." | 1.37 | A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer. ( Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Mihara, Y; Miyazaki, T; Takayama, T; Takayama, Y; Tamegai, H; Watanabe, M, 2011) |
| "Complications of esophageal cancer are particularly frequent in cases of hypopharyngeal cancer in comparison to other head and neck tumors." | 1.36 | [Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma]. ( Egawa, S; Furuya, A; Kobayashi, S; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H, 2010) |
| "The diagnosis was the esophageal cancer (type 2, 11 cm) with big lymph node metastasis on cardia (8 cm), and also pathologically poorly differentiated squamous cell carcinoma from two legions." | 1.35 | [A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home]. ( Doi, T; Handa, R; Hoshi, M; Iijimal, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Ooshima, S, 2008) |
| "We present a case of esophageal cancer with multiple lymph node metastases successfully performed early response evaluation for preoperative chemotherapy by FDG-PET." | 1.35 | [Case of esophageal cancer successfully performed in early response evaluation for preoperative chemotherapy by FDG-PET]. ( Arakaki, K; Isa, T; Kaneshiro, T; Nakachi, A; Nishimaki, T; Shiroma, H; Teruya, T; Yamamoto, H, 2008) |
| "Further examination showed esophageal cancer had metastasized to the cervical lymph nodes and invaded the trachea." | 1.35 | [Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers]. ( Hayashi, T; Hirano, N; Hoteya, S; Iizuka, T; Kikuchi, D; Mitani, T; Miyata, Y; Nakamura, M; Ochiai, Y; Sakurada, T; Yahagi, N, 2009) |
| "To investigate the efficacy and toxicity of nedaplatin combined with tegafur in the treatment for patients with advanced esophageal cancer." | 1.35 | [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer]. ( Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008) |
| "A 64-year-old woman with advanced esophageal cancer underwent chemotherapy with docetaxel/5-FU/CDDP (DFP)." | 1.35 | [Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy]. ( Honda, J; Matsuoka, H; Miyoshi, T; Seike, J; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y, 2008) |
| "He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy)." | 1.34 | [Recurrent esophageal cancer with complete response to TS-1 chemotherapy]. ( Chinen, T; Fujita, J; Hirata, T; Hokama, A; Kinjo, F; Kinjo, N; Nakachi, N; Nakamoto, M; Uchima, N; Watanabe, T, 2007) |
| "Thirty-seven patients with advanced esophageal cancer were admitted between March 2002 and April 2005." | 1.34 | Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. ( Choi, CW; Choi, IK; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sung, HJ, 2007) |
| "A 62-year-old woman with Barrett's esophageal cancer was hospitalized." | 1.34 | Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer. ( Azuma, M; Higuchi, K; Katada, C; Koizumi, W; Nakatani, K; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S, 2007) |
| "This chemotherapy made it possible to treat liver and lymph node metastasis in an ambulatory setting." | 1.33 | [A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination]. ( Hashimoto, Y; Hayashidani, Y; Morifuji, M; Murakami, Y; Sudo, A; Sueda, T; Sugiyama, Y; Uemura, K, 2006) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 1.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "We report a patient with advanced esophageal cancer who achieved a complete response to combination chemotherapy of TS-1, docetaxel and CDDP." | 1.33 | [Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer]. ( Kitakata, H; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K, 2006) |
| "A 65-year-old man was diagnosed as esophageal cancer with multiple liver metastases (S2 10 mm, S7 10 mm, S8 15 mm)." | 1.33 | [A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy]. ( Doi, K; Furuhashi, S; Ishihara, A; Ishimoto, T; Kikuchi, N; Ogata, K; Ogawa, M; Ohchi, T, 2006) |
| "Treatment of Barrett's esophageal cancer is often conducted in accordance with the principles of treatment of esophageal squamous cell carcinoma, and surgical resection represents the most effective treatment." | 1.32 | [A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy]. ( Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2003) |
| "A 70-year-old patient with advanced esophageal cancer with invasion to the aorta was treated by combined chemotherapy of TS-1 and CDDP with radiotherapy." | 1.32 | [Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy]. ( Doi, R; Indou, T; Iwase, H; Iyo, T; Kaida, S; Nakarai, K; Okeya, M; Shimada, M, 2004) |
| "Synchronous esophageal and gastric cancer were diagnosed by endoscopy and barium swallow." | 1.32 | [A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation]. ( Fujiwara, Y; Fukuhara, K; Harada, S; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2004) |
| "A 66-year-old patient, who had advanced esophageal cancer with lymph node metastasis, was treated by neoadjuvant chemo-radiotherapy, followed by curative surgery." | 1.32 | [A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy]. ( Kabashima, A; Matsusaka, T; Nishizaki, T; Ojima, Y; Sakaguchi, Y; Shimabukuro, R; Tashiro, H; Yamamoto, H; Yamamura, S, 2004) |
| "Gastrointestinal endoscopy showed esophageal cancer invading the gastric fundus." | 1.32 | Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin. ( Doi, R; Indo, T; Iwase, H; Kaida, S; Kato, E; Nakarai, K; Okeya, M; Shimada, M; Tsuzuki, T, 2004) |
| "A 51-year-old male patient with esophageal cancer and cervical, thoracic and celiac artery lymph node metastases was treated by combination chemotherapy of TS-1 and cisplatin." | 1.32 | [A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin]. ( Doi, R; Iwase, H; Kaida, S; Nakarai, K; Okeya, M; Shimada, M; Tsuzuki, T, 2004) |
| " After 7 days of treatment, grade 3 anorexia appeared, so the dosage of TS-1 was reduced to 25 mg/day." | 1.32 | [A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient]. ( Hasegawa, S; Hattori, H; Imazu, H; Komori, Y; Masui, T; Matsubara, T; Nagai, K; Nakamura, Y; Ochiai, M; Sakurai, Y; Syoji, M; Tonomura, S; Uyama, I; Yoshida, I, 2004) |
| " Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i." | 1.31 | [A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1]. ( Abe, S; Kitago, M; Kojima, M; Kurihara, H; Ogihara, T; Sasanuma, H; Tamura, H; Wada, M, 2002) |
| "A 77-year-old man with advanced esophageal cancer with tracheal and esophageal obstruction underwent continuous low-dose FP chemotherapy for a total of seven weeks, resulting in a complete response (CR) and disappearance of the esophago-tracheal fistula." | 1.31 | [A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer]. ( Hasebe, K; Sasaki, S; Takamura, H; Urade, M; Yagi, M, 2002) |
| "The patient was a 78-year-old man." | 1.31 | [A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful]. ( Fujiwara, Y; Fukuhara, K; Hashimoto, Y; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Takada, N; Takemura, M; Tanaka, Y; Ueno, M, 2002) |
| "Thus, gastric cancer was treated by chemotherapy and esophageal cancer by concurrent chemoradiotherapy with chemotherapy used for gastric cancer." | 1.31 | [Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP]. ( Hiraiwa, A; Indo, T; Iwase, H; Iyo, T; Kaida, S; Mizuno, T; Nakamura, M; Nakarai, K, 2002) |
| "Thus, this case was diagnosed as esophageal cancer, but surgery was deemed inappropriate due to the patient's advanced age." | 1.30 | [A case of esophageal cancer with excellent response to oral UFT treatment]. ( Haga, S; Hirai, M; Kajiwara, T; Naritaka, Y; Ogawa, K; Otani, Y, 1999) |
| "The treatment of upper thoracic esophageal cancer remains challenging, and combined treatment is necessary to improve the outcome." | 1.30 | Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma. ( Doki, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yamamoto, M; Yano, M, 1999) |
| "Specimens from six clinical cases of esophageal cancer were transplanted under the renal capsule of AF nude mice, and chemosensitivity to anticancer drugs (UFT, CDDP) was evaluated by measuring tumor size (SRC)." | 1.29 | [Light and electron microscopic examination compared to evaluation by tumor size in subrenal capsule assay for chemosensitivity testing in esophageal cancer]. ( Akao, S; Ishikawa, H; Kiumi, F; Oya, M, 1995) |
| "Evaluability of gastric and breast cancers was very low because of the poor growth of the grafts irrespective of the immunity of host animals." | 1.29 | [Evaluation of subrenal capsule assay (SRC) for clinical cancers]. ( Akao, S; Ishikawa, H; Iwami, N; Kiumi, F; Oya, M; Sasaki, K; Terada, H, 1996) |
| "The authors report a case with esophageal cancer who had undergone a non-curative resection and showed a recurrence." | 1.28 | [A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations]. ( Fujimura, N; Ishida, C; Koyama, S; Maezato, K; Makino, N; Matsukawa, Y; Matsumoto, K; Mizuno, Y; Naitoh, M; Yamamoto, E, 1992) |
| "Thirty-five consecutive esophageal cancer patients were treated by a combination regimen COPU (CTX 600-800 mg/m2, IV, on days 1, 8, 15 at 8 PM; VCR 1." | 1.28 | [COPU regimen in the treatment of 35 esophageal cancers]. ( Qi, WB, 1989) |
| "We report two patients with esophageal cancer who responded to UFT." | 1.27 | [UFT in esophageal cancer: a report of two cases]. ( Kagami, Y; Narimatsu, N; Nishio, M; Saitoh, A; Sakurai, T, 1987) |
| "Three patients with esophageal cancer, who were treated by FT+BrdU+radiation with good results, are reported." | 1.27 | [Experiences with FT+BrdU+radiation therapy of esophageal cancer]. ( Hanyu, F; Ide, H; Kobayashi, S; Muto, H; Nakagawa, M; Shimamura, Y; Takasaki, K; Tanaka, S; Yamada, A; Yamamoto, M, 1987) |
| "These were; EH-1 established from esophageal cancer, SH-6 from gastric cancer and CH-3 from colon cancer." | 1.27 | Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Saeki, T; Takagami, S; Wang, DC; Yamaguchi, M; Yoshinaka, K, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (11.49) | 18.7374 |
| 1990's | 13 (8.78) | 18.2507 |
| 2000's | 48 (32.43) | 29.6817 |
| 2010's | 63 (42.57) | 24.3611 |
| 2020's | 7 (4.73) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J | 1 |
| Zhou, S | 1 |
| Luo, Y | 1 |
| Liu, A | 1 |
| Zhao, J | 1 |
| Lei, J | 1 |
| Yu, J | 1 |
| Zhang, C | 3 |
| Song, X | 1 |
| Zhang, N | 1 |
| Wang, Y | 2 |
| Zhang, S | 2 |
| Kudo, R | 1 |
| Manaka, D | 1 |
| Ikeda, Y | 1 |
| Ota, T | 1 |
| Hamasu, S | 1 |
| Konishi, S | 1 |
| Nishitai, R | 1 |
| Yu, GM | 2 |
| Zhang, M | 2 |
| Liu, D | 1 |
| Wu, W | 1 |
| Gong, LB | 1 |
| Kawazoe, A | 1 |
| Yamaguchi, K | 4 |
| Yasui, H | 1 |
| Negoro, Y | 1 |
| Azuma, M | 2 |
| Amagai, K | 1 |
| Hara, H | 1 |
| Baba, H | 1 |
| Tsuda, M | 1 |
| Hosaka, H | 1 |
| Kawakami, H | 1 |
| Oshima, T | 1 |
| Omuro, Y | 1 |
| Machida, N | 3 |
| Esaki, T | 1 |
| Yoshida, K | 4 |
| Nishina, T | 2 |
| Komatsu, Y | 1 |
| Han, SR | 1 |
| Shiratori, S | 1 |
| Shitara, K | 4 |
| Kanda, M | 1 |
| Koike, M | 1 |
| Iwata, N | 1 |
| Shimizu, D | 1 |
| Tanaka, C | 1 |
| Hattori, N | 1 |
| Hayashi, M | 1 |
| Yamada, S | 1 |
| Omae, K | 1 |
| Nakayama, G | 1 |
| Kodera, Y | 1 |
| Chi, D | 1 |
| Chen, B | 1 |
| Guo, S | 1 |
| Bai, K | 1 |
| Ma, H | 1 |
| Hu, Y | 1 |
| Li, Q | 1 |
| Zhu, Y | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Li, J | 2 |
| Xu, H | 1 |
| Luo, L | 1 |
| Jia, Y | 2 |
| Song, GM | 1 |
| Tian, X | 1 |
| Liu, XL | 1 |
| Chen, H | 1 |
| Zhou, JG | 1 |
| Bian, W | 1 |
| Chen, WQ | 1 |
| Wang, F | 1 |
| Fan, QX | 2 |
| Wang, HH | 1 |
| Han, DM | 1 |
| Song, NS | 1 |
| Lu, H | 1 |
| Ter Veer, E | 2 |
| Ngai, LL | 2 |
| Valkenhoef, GV | 1 |
| Mohammad, NH | 1 |
| Anderegg, MCJ | 1 |
| van Oijen, MGH | 2 |
| van Laarhoven, HWM | 2 |
| Wen, Y | 1 |
| Zhao, Z | 1 |
| Miao, J | 1 |
| Yang, Q | 1 |
| Gui, Y | 1 |
| Sun, M | 1 |
| Tian, H | 1 |
| Jia, Q | 1 |
| Liao, D | 1 |
| Yang, C | 1 |
| Du, X | 1 |
| Komoto, S | 2 |
| Noma, K | 2 |
| Maeda, N | 2 |
| Matsumi, Y | 2 |
| Ninomiya, T | 2 |
| Tanabe, S | 3 |
| Shirakawa, Y | 2 |
| Fujiwara, T | 2 |
| Nishizaki, M | 1 |
| Kagawa, S | 1 |
| Wang, W | 2 |
| Xing, D | 1 |
| Song, Y | 1 |
| Liu, F | 1 |
| Kuroda, J | 1 |
| Aoki, H | 2 |
| Kondou, N | 1 |
| Sumita, T | 1 |
| Itoh, K | 1 |
| Agawa, S | 1 |
| Ojima, T | 1 |
| Nakamura, M | 6 |
| Nakamori, M | 1 |
| Katsuda, M | 1 |
| Hayata, K | 1 |
| Maruoka, S | 1 |
| Shimokawa, T | 1 |
| Yamaue, H | 1 |
| Sun, S | 1 |
| Yu, H | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Wu, X | 1 |
| Wang, J | 2 |
| Chang, J | 1 |
| Venerito, M | 1 |
| Huang, J | 2 |
| Xu, B | 1 |
| Liu, Y | 1 |
| Lu, P | 2 |
| Ba, Y | 1 |
| Wu, L | 1 |
| Bai, Y | 1 |
| Feng, J | 1 |
| Cheng, Y | 2 |
| Wen, L | 1 |
| Yuan, X | 1 |
| Ma, C | 1 |
| Hu, C | 1 |
| Fan, Q | 1 |
| Wang, X | 3 |
| Li, C | 1 |
| Han, C | 1 |
| Wang, P | 1 |
| Pang, Q | 1 |
| Chen, J | 1 |
| Sun, X | 1 |
| Wang, L | 1 |
| Zhang, W | 1 |
| Lin, Y | 1 |
| Ge, X | 1 |
| Zhou, Z | 1 |
| Ni, W | 1 |
| Chang, X | 1 |
| Liang, J | 1 |
| Deng, L | 1 |
| Zhao, Y | 2 |
| Xiao, Z | 1 |
| Liu, X | 1 |
| Jin, J | 1 |
| Cai, H | 1 |
| Huang, H | 1 |
| Zhao, G | 1 |
| Zhou, Y | 1 |
| Wu, J | 1 |
| Du, C | 1 |
| Long, Z | 1 |
| Fang, Y | 1 |
| Ma, M | 1 |
| Li, G | 1 |
| Zhou, M | 1 |
| Yin, J | 1 |
| Zhu, X | 1 |
| Zhu, J | 1 |
| Sheng, W | 1 |
| Huang, D | 1 |
| Zhu, H | 1 |
| Zhang, Z | 3 |
| Lu, Q | 1 |
| Xie, L | 1 |
| Ito, T | 2 |
| Honma, Y | 1 |
| Hirano, H | 1 |
| Shoji, H | 1 |
| Okita, N | 1 |
| Iwasa, S | 1 |
| Takashima, A | 1 |
| Kato, K | 2 |
| Boku, N | 3 |
| Kobayashi, R | 1 |
| Yamashita, H | 2 |
| Okuma, K | 2 |
| Shiraishi, K | 1 |
| Ohtomo, K | 2 |
| Nakagawa, K | 2 |
| Akutsu, Y | 1 |
| Kono, T | 1 |
| Uesato, M | 1 |
| Hoshino, I | 1 |
| Narushima, K | 1 |
| Hanaoka, T | 1 |
| Tochigi, T | 1 |
| Semba, Y | 1 |
| Qin, W | 1 |
| Matsubara, H | 1 |
| Iwase, H | 9 |
| Shimada, M | 6 |
| Tsuzuki, T | 3 |
| Hirashima, N | 1 |
| Okeya, M | 5 |
| Hibino, Y | 1 |
| Ryuge, N | 1 |
| Yokoi, M | 1 |
| Kida, Y | 1 |
| Kuno, T | 1 |
| Tanaka, Y | 6 |
| Kato, B | 1 |
| Esaki, M | 1 |
| Urata, N | 1 |
| Kato, E | 4 |
| Ajani, JA | 4 |
| Buyse, M | 1 |
| Lichinitser, M | 2 |
| Gorbunova, V | 2 |
| Bodoky, G | 3 |
| Douillard, JY | 1 |
| Cascinu, S | 2 |
| Heinemann, V | 1 |
| Zaucha, R | 1 |
| Carrato, A | 2 |
| Ferry, D | 1 |
| Moiseyenko, V | 3 |
| Park, I | 1 |
| Ryu, MH | 1 |
| Choi, YH | 1 |
| Kang, HJ | 1 |
| Yook, JH | 1 |
| Park, YS | 1 |
| Kim, HJ | 2 |
| Jung, HY | 2 |
| Lee, GH | 2 |
| Kim, KC | 1 |
| Kim, BS | 2 |
| Kang, YK | 1 |
| Takemura, M | 4 |
| Matsuyama, T | 1 |
| Nishibeppu, K | 1 |
| Matsumura, A | 1 |
| Ogino, S | 1 |
| Mugitani, T | 1 |
| Akami, T | 1 |
| Shimode, Y | 1 |
| Chang, H | 1 |
| Shin, SK | 1 |
| Cho, BC | 1 |
| Lee, CG | 1 |
| Kim, CB | 1 |
| Kim, DJ | 1 |
| Lee, JG | 1 |
| Hur, J | 1 |
| Lee, CY | 1 |
| Bae, MK | 1 |
| Kim, HR | 2 |
| Lee, SK | 1 |
| Park, JC | 1 |
| Lee, H | 1 |
| Kim, HI | 1 |
| Chung, H | 1 |
| Cha, J | 1 |
| Lee, YC | 1 |
| Kim, JH | 2 |
| Matsumoto, H | 4 |
| Kubota, H | 3 |
| Higashida, M | 4 |
| Yoden, E | 2 |
| Hiratsuka, J | 3 |
| Haruma, K | 1 |
| Hirai, T | 5 |
| Issaka, A | 1 |
| Ermerak, NO | 1 |
| Bilgi, Z | 1 |
| Kara, VH | 1 |
| Celikel, CA | 1 |
| Batirel, HF | 1 |
| Yoon, DH | 1 |
| Jang, G | 1 |
| Kim, YH | 2 |
| Kim, JY | 1 |
| Song, HY | 1 |
| Cho, KJ | 1 |
| Ryu, JS | 1 |
| Kim, SB | 1 |
| Fuse, N | 2 |
| Kuboki, Y | 1 |
| Kuwata, T | 1 |
| Kadowaki, S | 1 |
| Shinozaki, E | 1 |
| Yuki, S | 1 |
| Ooki, A | 1 |
| Kajiura, S | 1 |
| Kimura, T | 1 |
| Yamanaka, T | 1 |
| Nagatsuma, AK | 1 |
| Yoshino, T | 1 |
| Ochiai, A | 1 |
| Ohtsu, A | 2 |
| Scheulen, ME | 1 |
| Rivera, F | 1 |
| Jassem, J | 1 |
| Vynnychenko, I | 2 |
| Prausová, J | 1 |
| Van Laethem, JL | 1 |
| Natsume, S | 1 |
| Iwasaki, Y | 1 |
| Yajima, K | 1 |
| Yuu, K | 1 |
| Oohinata, R | 1 |
| Ishiyama, S | 1 |
| Takahashi, K | 2 |
| Maeda, Y | 1 |
| Nagai, Y | 1 |
| Kato, T | 3 |
| Harano, M | 1 |
| Satoh, D | 1 |
| Choda, Y | 1 |
| Tokumoto, N | 1 |
| Kanazawa, T | 1 |
| Matsukawa, H | 1 |
| Ojima, Y | 2 |
| Idani, H | 1 |
| Shiozaki, S | 1 |
| Okajima, M | 1 |
| Ninomiya, M | 1 |
| Ohno, S | 1 |
| Kurokawa, Y | 1 |
| Takiguchi, S | 1 |
| Miyazaki, Y | 1 |
| Takahashi, T | 3 |
| Yamasaki, M | 1 |
| Miyata, H | 1 |
| Nakajima, K | 1 |
| Mori, M | 1 |
| Doki, Y | 2 |
| Tahara, M | 1 |
| Mizusawa, J | 2 |
| Sato, A | 1 |
| Nihei, K | 1 |
| Kanato, K | 1 |
| Yamazaki, K | 1 |
| Muro, K | 1 |
| Takaishi, H | 1 |
| Kataoka, K | 1 |
| Tokunaga, M | 1 |
| Katayama, H | 1 |
| Tomita, T | 1 |
| Nakamura, K | 2 |
| Sano, T | 1 |
| Terashima, M | 2 |
| Sasako, M | 1 |
| Haga, A | 1 |
| Takenaka, R | 1 |
| Kiritoshi, T | 1 |
| Nakao, E | 1 |
| Iijima, S | 1 |
| Tsujimura, N | 1 |
| Matsumoto, T | 1 |
| Takemoto, H | 1 |
| Takachi, K | 1 |
| Nishioka, K | 1 |
| Oshima, S | 1 |
| Uemura, Y | 1 |
| Yao, B | 1 |
| Tan, B | 1 |
| Wang, C | 1 |
| Song, Q | 1 |
| Guan, S | 1 |
| Ma, Y | 1 |
| Huang, X | 1 |
| Sun, Y | 1 |
| Tanahashi, T | 1 |
| Okumura, N | 1 |
| Matsuhashi, N | 1 |
| Haj Mohammad, N | 1 |
| van Valkenhoef, G | 1 |
| Mali, RMA | 1 |
| Anderegg, MC | 1 |
| Kano, K | 1 |
| Sato, T | 2 |
| Maezawa, Y | 1 |
| Segami, K | 1 |
| Nakajima, T | 1 |
| Ikeda, K | 1 |
| Hayashi, T | 2 |
| Yamada, T | 2 |
| Yamamoto, N | 1 |
| Ohshima, T | 1 |
| Yukawa, N | 1 |
| Rino, Y | 1 |
| Masuda, M | 1 |
| Ogata, T | 1 |
| Cho, H | 1 |
| Yoshikawa, T | 1 |
| Wang, HY | 1 |
| Yao, ZH | 1 |
| Tang, H | 1 |
| Jin, SL | 1 |
| Zhou, WP | 1 |
| Yao, SN | 1 |
| Yang, SJ | 1 |
| Liu, YY | 1 |
| Luo, SX | 2 |
| Nie, K | 1 |
| Geng, C | 1 |
| Zhang, L | 1 |
| Liu, S | 1 |
| Wang, R | 2 |
| Zou, X | 1 |
| Ji, Y | 1 |
| Murakami, K | 1 |
| Tamura, S | 1 |
| Takeno, A | 1 |
| Ishida, T | 1 |
| Kuwahara, R | 1 |
| Akiyama, Y | 1 |
| Sakamoto, T | 1 |
| Inatome, J | 1 |
| Naito, A | 1 |
| Katsura, Y | 1 |
| Ohmura, Y | 1 |
| Kagawa, Y | 1 |
| Egawa, C | 1 |
| Takeda, Y | 1 |
| Cho, SH | 1 |
| Shim, HJ | 1 |
| Lee, SR | 1 |
| Ahn, JS | 1 |
| Yang, DH | 1 |
| Kim, YK | 1 |
| Nam, TK | 1 |
| Lee, JJ | 1 |
| Chung, IJ | 1 |
| Isa, T | 1 |
| Kaneshiro, T | 1 |
| Yamamoto, H | 2 |
| Nakachi, A | 1 |
| Teruya, T | 1 |
| Shiroma, H | 1 |
| Arakaki, K | 1 |
| Nishimaki, T | 1 |
| Kojima, T | 1 |
| Matsui, T | 1 |
| Uemura, T | 1 |
| Fujimitsu, Y | 1 |
| Kure, N | 1 |
| Mochizuki, Y | 2 |
| Kojima, H | 1 |
| Zhao, YF | 1 |
| Lu, TY | 1 |
| Han, JW | 1 |
| Wang, JS | 1 |
| Lu, SP | 1 |
| Wang, GJ | 1 |
| Geng, L | 1 |
| Zhang, MZ | 1 |
| Ma, ZY | 1 |
| Song, M | 1 |
| Wu, XA | 1 |
| Chen, XB | 1 |
| Jiao, ZM | 1 |
| Wang, RL | 1 |
| Sugawara, H | 1 |
| Ichiki, M | 1 |
| Sai, K | 1 |
| Kamata, K | 1 |
| Ansai, M | 1 |
| Nakano, Y | 1 |
| Kawamura, M | 1 |
| Ichinose, A | 1 |
| Miyazaki, S | 1 |
| Kikuchi, D | 1 |
| Iizuka, T | 1 |
| Hoteya, S | 1 |
| Miyata, Y | 1 |
| Mitani, T | 1 |
| Ochiai, Y | 1 |
| Sakurada, T | 1 |
| Hirano, N | 1 |
| Yahagi, N | 1 |
| Saito, A | 1 |
| Kaida, Y | 1 |
| Murakami, H | 3 |
| Hirabayashi, Y | 2 |
| Oka, Y | 2 |
| Okumura, H | 2 |
| Uragami, A | 1 |
| Yamashita, K | 3 |
| Ohyama, M | 1 |
| Ikeda, H | 1 |
| Okabe, M | 1 |
| Morimoto, Y | 1 |
| Kawamoto, K | 1 |
| Sano, K | 1 |
| Paku, T | 1 |
| Imai, S | 1 |
| Yoshida, Y | 1 |
| Ogasahara, K | 1 |
| Rodriguez, W | 1 |
| Garin, A | 1 |
| Lang, I | 1 |
| Falcon, S | 1 |
| Hiraki, M | 2 |
| Tanaka, M | 1 |
| Sato, S | 1 |
| Kai, K | 1 |
| Morito, K | 1 |
| Kobayashi, K | 2 |
| Noshiro, H | 1 |
| Tokunaga, O | 1 |
| Miyazaki, K | 1 |
| Iijimal, S | 1 |
| Makari, Y | 1 |
| Handa, R | 1 |
| Ooshima, S | 1 |
| Miyake, Y | 1 |
| Hoshi, M | 1 |
| Doi, T | 1 |
| Kurokawa, E | 1 |
| Kikkawa, N | 1 |
| Matsuda, S | 1 |
| Takahashi, M | 1 |
| Watanabe, J | 1 |
| Yabuno, T | 1 |
| Kito, F | 1 |
| Kunisaki, C | 1 |
| Shimane, T | 1 |
| Mori, T | 1 |
| Ono, T | 1 |
| Egawa, S | 1 |
| Furuya, A | 1 |
| Kobayashi, S | 2 |
| Sanbe, T | 1 |
| Suzaki, H | 1 |
| Shinoto, M | 1 |
| Shioyama, Y | 1 |
| Sasaki, T | 2 |
| Ohura, H | 1 |
| Toh, Y | 1 |
| Higaki, Y | 1 |
| Yamaguchi, T | 1 |
| Ohnishi, K | 1 |
| Atsumi, K | 1 |
| Hirata, H | 1 |
| Honda, H | 1 |
| Liu, CX | 1 |
| Li, XY | 1 |
| Gao, XS | 1 |
| Takayama, Y | 1 |
| Kochi, M | 3 |
| Fujii, M | 4 |
| Kanamori, N | 3 |
| Kaiga, T | 2 |
| Mihara, Y | 2 |
| Miyazaki, T | 2 |
| Tamegai, H | 1 |
| Watanabe, M | 1 |
| Takayama, T | 4 |
| Fujiwara, H | 2 |
| Koeda, K | 1 |
| Konosu, M | 1 |
| Hosoi, N | 1 |
| Tamasawa, Y | 1 |
| Sase, M | 1 |
| Tsukahara, T | 1 |
| Ushio, A | 1 |
| Taguchi, M | 1 |
| Wakabayashi, G | 1 |
| Osada, S | 1 |
| Wang, JL | 1 |
| Bi, Z | 1 |
| Zou, JW | 1 |
| Gu, XM | 1 |
| Ebisui, C | 1 |
| Okada, K | 1 |
| Nishigaki, T | 1 |
| Owada, Y | 1 |
| Nagase, H | 1 |
| Mukai, R | 1 |
| Momozane, T | 1 |
| Murakami, M | 1 |
| Ide, Y | 1 |
| Yanagisawa, T | 1 |
| Murata, K | 1 |
| Yokouchi, H | 1 |
| Tamai, M | 1 |
| Kinuta, M | 1 |
| Yoneda, M | 1 |
| Shiozaki, A | 1 |
| Komatsu, S | 1 |
| Ichikawa, D | 1 |
| Okamoto, K | 1 |
| Murayama, Y | 1 |
| Kuriu, Y | 1 |
| Ikoma, H | 1 |
| Nakanishi, M | 1 |
| Ochiai, T | 1 |
| Kokuba, Y | 1 |
| Otsuji, E | 1 |
| Nakamura, T | 2 |
| Ota, M | 1 |
| Narumiya, K | 1 |
| Shirai, Y | 1 |
| Yamamoto, M | 3 |
| Kuramochi, H | 1 |
| Hayashi, K | 2 |
| Nakajima, Y | 1 |
| Fujiwara, N | 1 |
| Ryotokuji, T | 1 |
| Ohta, S | 1 |
| Okada, T | 1 |
| Miyawaki, Y | 1 |
| Hoshino, A | 1 |
| Jirawat, S | 1 |
| Tokairin, Y | 1 |
| Kawada, K | 1 |
| Nishikage, T | 1 |
| Nagai, K | 2 |
| Kawano, T | 1 |
| Peer, CJ | 1 |
| McManus, TJ | 1 |
| Hurwitz, HI | 2 |
| Petros, WP | 2 |
| Matsuno, Y | 1 |
| Funada, T | 1 |
| Holländer, C | 1 |
| Baeksgaard, L | 1 |
| Sorensen, M | 1 |
| Albertsson, P | 1 |
| Damstrup, L | 1 |
| Lassen, U | 1 |
| Kawabe, Y | 2 |
| Nakashima, H | 1 |
| Umemoto, S | 1 |
| Hosaka, S | 1 |
| Kikutake, T | 1 |
| Okubo, S | 1 |
| Maeno, H | 1 |
| Inada, K | 1 |
| Nagao, S | 1 |
| Kawamoto, S | 1 |
| Yoshida, T | 4 |
| Abe, S | 1 |
| Kojima, M | 1 |
| Kurihara, H | 1 |
| Tamura, H | 1 |
| Kitago, M | 1 |
| Sasanuma, H | 1 |
| Wada, M | 1 |
| Ogihara, T | 1 |
| Takamura, H | 1 |
| Sasaki, S | 1 |
| Hasebe, K | 1 |
| Urade, M | 1 |
| Yagi, M | 1 |
| Osugi, H | 3 |
| Lee, S | 3 |
| Taguchi, S | 2 |
| Kaneko, M | 2 |
| Fukuhara, K | 3 |
| Fujiwara, Y | 3 |
| Nishizawa, S | 3 |
| Kinoshita, H | 3 |
| Wakabayashi, K | 2 |
| Hayashi, S | 1 |
| Masuda, H | 1 |
| Karube, H | 1 |
| Ookame, H | 1 |
| Sakamoto, N | 1 |
| Tanaka, A | 1 |
| Funai, S | 1 |
| Ohtsuka, H | 1 |
| Yoshifuji, T | 1 |
| Shindo, K | 1 |
| Shiozaki, H | 3 |
| Kamei, A | 1 |
| Nakarai, K | 6 |
| Iyo, T | 3 |
| Kaida, S | 6 |
| Indo, T | 4 |
| Horiuchi, Y | 1 |
| Kusugami, K | 1 |
| Indou, T | 1 |
| Doi, R | 4 |
| Harada, S | 1 |
| Imazu, H | 1 |
| Ochiai, M | 1 |
| Sakurai, Y | 1 |
| Komori, Y | 1 |
| Uyama, I | 1 |
| Matsubara, T | 1 |
| Hasegawa, S | 1 |
| Nakamura, Y | 1 |
| Syoji, M | 1 |
| Yoshida, I | 1 |
| Masui, T | 1 |
| Tonomura, S | 1 |
| Hattori, H | 1 |
| Tuzuki, T | 1 |
| Akagi, Y | 1 |
| Hashimoto, Y | 3 |
| Takiyama, W | 1 |
| Mukaida, H | 1 |
| Murakami, Y | 2 |
| Ito, K | 1 |
| Sakaguchi, Y | 1 |
| Kabashima, A | 1 |
| Shimabukuro, R | 1 |
| Yamamura, S | 1 |
| Nishizaki, T | 1 |
| Tashiro, H | 1 |
| Matsusaka, T | 1 |
| Inaba, H | 1 |
| Miyazaki, A | 1 |
| Tsuda, T | 1 |
| Akasaka, H | 1 |
| Kobayashi, M | 1 |
| Okamoto, M | 1 |
| Ogihara, K | 1 |
| Yamauchi, S | 1 |
| Koro, T | 1 |
| Katoh, N | 1 |
| Fujita, K | 1 |
| Watanabe, Y | 2 |
| Abiko, R | 1 |
| Nakaya, S | 1 |
| Kitajima, S | 1 |
| Hoshikawa, Y | 1 |
| Kimura, M | 1 |
| Itoh, F | 1 |
| Yunotani, S | 1 |
| Noguchi, R | 1 |
| Shinozaki, Y | 1 |
| Tani, H | 1 |
| Sakai, M | 1 |
| Ishimitsu, T | 1 |
| Tabuchi, M | 1 |
| Tedesco, KL | 1 |
| Berlin, J | 1 |
| Blanke, CD | 1 |
| Teng, M | 1 |
| Choy, H | 1 |
| Roberts, J | 1 |
| Beauchamp, RD | 1 |
| Leach, S | 1 |
| Wyman, K | 1 |
| Tarpley, J | 1 |
| Shyr, Y | 1 |
| Caillouette, C | 1 |
| Chakravarthy, B | 1 |
| Ohchi, T | 1 |
| Kikuchi, N | 1 |
| Doi, K | 1 |
| Ogata, K | 1 |
| Ishimoto, T | 1 |
| Furuhashi, S | 1 |
| Ogawa, M | 2 |
| Ishihara, A | 1 |
| Masuda, A | 1 |
| Tongu, M | 1 |
| Hiraku, O | 1 |
| Etou, T | 1 |
| Sasaki, K | 2 |
| Atsuda, K | 1 |
| Morinaga, S | 1 |
| Suzuki, T | 2 |
| Suzuki, Y | 1 |
| Osaku, M | 1 |
| Miyagawa, T | 1 |
| Asanuma, F | 1 |
| Yamada, Y | 1 |
| Sugiyama, Y | 1 |
| Morifuji, M | 1 |
| Uemura, K | 1 |
| Hayashidani, Y | 1 |
| Sudo, A | 1 |
| Sueda, T | 1 |
| Yasumoto, K | 1 |
| Kitakata, H | 1 |
| Omote, K | 1 |
| Takahashi, Y | 1 |
| Munakata, M | 1 |
| Ishiguro, A | 1 |
| Hoshi, Y | 1 |
| Okada, R | 1 |
| Tomioka, R | 1 |
| Mitobe, S | 1 |
| Sakata, Y | 1 |
| Ebina, A | 1 |
| Aoki, M | 1 |
| Seike, J | 3 |
| Honda, J | 3 |
| Miyoshi, T | 3 |
| Umemoto, A | 2 |
| Tangoku, A | 3 |
| Urakami, A | 1 |
| Imajyo, Y | 1 |
| Tsunoda, T | 1 |
| Yasumura, T | 1 |
| Maruyama, T | 1 |
| Kaji, S | 1 |
| Yagawa, A | 1 |
| Ozawa, T | 1 |
| Watanabe, T | 1 |
| Chinen, T | 1 |
| Nakachi, N | 1 |
| Nakamoto, M | 1 |
| Uchima, N | 1 |
| Hirata, T | 1 |
| Hokama, A | 1 |
| Kinjo, N | 1 |
| Kinjo, F | 1 |
| Fujita, J | 1 |
| Nakatani, K | 1 |
| Koizumi, W | 1 |
| Nishimura, K | 1 |
| Shimoda, T | 1 |
| Katada, C | 1 |
| Higuchi, K | 1 |
| Saigenji, K | 1 |
| Choi, IK | 1 |
| Seo, HY | 1 |
| Sung, HJ | 1 |
| Park, KH | 1 |
| Kim, SJ | 1 |
| Oh, SC | 1 |
| Seo, JH | 1 |
| Choi, CW | 1 |
| Shin, SW | 1 |
| Kim, JS | 1 |
| Sou, K | 1 |
| Czito, BG | 1 |
| Cohen, DP | 1 |
| Kelsey, CR | 1 |
| Lockhart, AC | 1 |
| Bendell, JC | 1 |
| Willett, CG | 1 |
| D'Amico, TA | 1 |
| Truax, R | 1 |
| Cen, P | 1 |
| Tokuhara, T | 1 |
| Okuda, T | 1 |
| Sakata, C | 1 |
| Nishikawa, M | 1 |
| Morita, R | 1 |
| Motoyama, S | 1 |
| Mori, K | 1 |
| Maruyama, K | 1 |
| Sato, Y | 1 |
| Usami, S | 1 |
| Suzuki, H | 1 |
| Ogawa, J | 1 |
| Takada, J | 1 |
| Okuda, K | 1 |
| Tani, C | 1 |
| Kenno, S | 1 |
| Oguro, S | 1 |
| Shimokuni, T | 1 |
| Aoki, T | 1 |
| Nagaoka, Y | 1 |
| Uno, Y | 1 |
| Hamada, H | 1 |
| Matsuoka, H | 1 |
| Yuasa, Y | 1 |
| Yamai, H | 1 |
| Sugimachi, K | 2 |
| Inokuchi, K | 2 |
| Okudaira, Y | 2 |
| Yaita, A | 1 |
| Kai, H | 1 |
| Kuwano, H | 1 |
| Matsuura, H | 1 |
| Ogawa, Y | 1 |
| Fujimoto, J | 1 |
| Kido, Y | 1 |
| Miyamoto, T | 1 |
| Tane, H | 1 |
| Kokunai, I | 1 |
| Ueno, K | 1 |
| Ibayashi, J | 1 |
| Matsuoka, S | 1 |
| Maezawa, S | 1 |
| Sakuma, M | 1 |
| Ohira, S | 1 |
| Wakui, A | 2 |
| Saito, T | 1 |
| Kabuto, T | 1 |
| Taniguchi, K | 1 |
| Furukawa, H | 1 |
| Iwanaga, T | 1 |
| Aoki, Y | 1 |
| Terasawa, T | 1 |
| Akao, S | 2 |
| Oya, M | 2 |
| Ishikawa, H | 2 |
| Kiumi, F | 2 |
| Hashimoto, T | 1 |
| Omura, K | 1 |
| Ishida, F | 1 |
| Matsumoto, M | 1 |
| Nomiyama, T | 1 |
| Nakae, J | 1 |
| Nishikawa, H | 1 |
| Iwami, N | 1 |
| Terada, H | 1 |
| Otani, Y | 1 |
| Hirai, M | 1 |
| Naritaka, Y | 1 |
| Haga, S | 1 |
| Ogawa, K | 1 |
| Kajiwara, T | 1 |
| Tsujinaka, T | 1 |
| Inoue, M | 1 |
| Yano, M | 1 |
| Monden, M | 1 |
| Seymour, MT | 1 |
| Dent, JT | 1 |
| Papamichael, D | 1 |
| Wilson, G | 1 |
| Cresswell, H | 1 |
| Slevin, ML | 1 |
| Ohsawa, H | 1 |
| Aiba, K | 1 |
| Sugiyama, K | 1 |
| Mizunuma, N | 1 |
| Takahashi, S | 1 |
| Ito, Y | 1 |
| Horikoshi, N | 1 |
| Shirasaka, T | 1 |
| Yamamitsu, S | 1 |
| Tsuji, A | 1 |
| Hirata, K | 1 |
| Mizuno, T | 1 |
| Hiraiwa, A | 1 |
| Takada, N | 1 |
| Ueno, M | 1 |
| Morise, K | 1 |
| Mizuno, Y | 1 |
| Makino, N | 1 |
| Matsumoto, K | 1 |
| Fujimura, N | 1 |
| Yamamoto, E | 1 |
| Ishida, C | 1 |
| Koyama, S | 1 |
| Naitoh, M | 1 |
| Maezato, K | 1 |
| Matsukawa, Y | 1 |
| Kanamaru, R | 1 |
| Hamabe, Y | 1 |
| Ikuta, H | 1 |
| Osawa, M | 1 |
| Kuroda, D | 1 |
| Usami, M | 1 |
| Katoh, M | 1 |
| Saitoh, Y | 1 |
| Hazama, S | 1 |
| Hayashi, H | 1 |
| Oka, M | 1 |
| Murakami, T | 1 |
| Fujimaki, M | 1 |
| Qi, WB | 1 |
| Imamura, M | 1 |
| Ohishi, K | 1 |
| Shimada, Y | 1 |
| Tobe, T | 1 |
| Arai, T | 1 |
| Hatano, Y | 1 |
| Hiraoka, M | 1 |
| Abe, M | 1 |
| Inoue, R | 1 |
| Ito, M | 1 |
| Shimizu, T | 1 |
| Nishino, S | 1 |
| Kikuchi, Y | 1 |
| Yoshikawa, H | 1 |
| Asano, A | 1 |
| Kagami, Y | 1 |
| Sakurai, T | 1 |
| Nishio, M | 1 |
| Narimatsu, N | 1 |
| Saitoh, A | 1 |
| Takasaki, K | 1 |
| Muto, H | 1 |
| Tanaka, S | 1 |
| Shimamura, Y | 1 |
| Ide, H | 1 |
| Nakagawa, M | 1 |
| Yamada, A | 1 |
| Hanyu, F | 1 |
| Nishiyama, M | 1 |
| Niimi, K | 1 |
| Takagami, S | 1 |
| Hirabayashi, N | 1 |
| Yamaguchi, M | 1 |
| Saeki, T | 1 |
| Yoshinaka, K | 1 |
| Wang, DC | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)[NCT03382600] | Phase 2 | 100 participants (Actual) | Interventional | 2018-03-26 | Completed | ||
| Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study[NCT02319187] | Phase 3 | 240 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691] | Phase 2/Phase 3 | 350 participants (Anticipated) | Interventional | 2016-10-31 | Completed | ||
| A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study)[NCT03013010] | Phase 3 | 682 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma[NCT05161572] | Phase 2 | 152 participants (Anticipated) | Interventional | 2021-09-28 | Recruiting | ||
| Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986] | Phase 2 | 46 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
| Toripalimab Combined With Docetaxel or Nab-paclitaxel in the Treatment of Advanced Gastric Cancer : a Single-arm, Open Label, Prospective Phase II Clinical Trial[NCT04563975] | Phase 2 | 54 participants (Anticipated) | Interventional | 2020-07-02 | Recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DCR was defined as the percentage of participants in the analysis population who have CR (disappearance of all target lesions), PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD), or stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD [≥20% increase in the SOD of target lesions]). Responses are according to iRECIST 1.1 as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 96.3 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 97.8 |
DCR was defined as the percentage of participants in the analysis population who have complete response (CR, disappearance of all target lesions), partial response (PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD), or stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD, ≥20% increase in the SOD of target lesions]). Responses are according to RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 96.3 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 97.8 |
For participants who demonstrated complete response (CR, disappearance of all target lesions) or partial response (PR, ≥30% decrease in the SOD of target lesions) according to iRECIST as assessed by BICR, DOR was defined as the time from the earliest date of qualifying response (CR or PR) until earliest date of progressive disease (PD, ≥20% increase in the SOD of target lesions) or death from any cause, whichever came first. DOR was censored at the last tumor assessment date if a responder did not have PD or death. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 10.6 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 9.5 |
For participants who demonstrated complete response (CR, disappearance of all target lesions) or partial response (PR, ≥30% decrease in the SOD of target lesions) according to RECIST 1.1 as assessed by BICR, DOR was defined as the time from the earliest date of qualifying response (CR or PR) until earliest date of progressive disease (PD, ≥20% increase in the SOD of target lesions) or death from any cause, whichever came first. DOR was censored at the last tumor assessment date if a responder did not have PD or death. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 10.6 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 9.5 |
An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 3 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 3 |
An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 54 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 46 |
For the primary efficacy analysis, ORR was defined as the percentage of participants who have a best response of complete response (CR, disappearance of all target lesions) or partial response (PR, at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) per RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 72.2 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 80.4 |
For the secondary efficacy analysis, ORR was defined as the percentage of participants whose best response based on imaging is CR (disappearance of all target lesions) or PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD) according to iRECIST as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 72.2 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 80.4 |
OS was defined as the time from the date of enrollment day to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. For these participants, date of last follow up was last visit date instead of death date. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 16.9 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 17.1 |
PFS was defined as the time from the date of enrollment day to the first documented PD (defined as ≥20% increase in the SOD of target lesions) or death due to any cause, whichever occurred first. Responses are according to iRECIST 1.1 as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 9.4 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 10.9 |
PFS was defined as the time from the date of enrollment day to the first documented PD (defined as ≥20% increase in the SOD of target lesions) or death due to any cause, whichever occurred first. Responses are according to RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 9.4 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 8.3 |
TTR was defined as the time from the date of enrollment day to the first date of confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD). Responses are according to RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 1.5 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 1.5 |
TTR was defined as the time from the date of enrollment day to the first date of confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD). Responses are according to iRECIST 1.1 as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 1.5 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 1.5 |
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 6.5 |
| 5-FU/Cisplatin | 5.8 |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 8.6 |
| 5-FU/Cisplatin | 7.9 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).
| Intervention | Percentage of patients in each group (Number) |
|---|---|
| S-1/Cisplatin | 29.1 |
| 5-FU/Cisplatin | 31.9 |
The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 4.8 |
| 5-FU/Cisplatin | 5.5 |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 3.8 |
| 5-FU/Cisplatin | 3.8 |
14 reviews available for tegafur and Esophageal Neoplasms
| Article | Year |
|---|---|
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junc | 2020 |
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junc | 2020 |
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junc | 2020 |
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junc | 2020 |
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm | 2020 |
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm | 2020 |
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm | 2020 |
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm | 2020 |
Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Dru | 2017 |
Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Dru | 2017 |
Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Dru | 2017 |
Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Dru | 2017 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2017 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2017 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2017 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2017 |
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug | 2017 |
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug | 2017 |
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug | 2017 |
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug | 2017 |
Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Humans; | 2018 |
Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Humans; | 2018 |
Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Humans; | 2018 |
Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Humans; | 2018 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, | 2015 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin | 2016 |
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell | 2010 |
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell | 2010 |
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell | 2010 |
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell | 2010 |
[Concurrent chemoradiation using daily low-dose CDDP and UFT-E for postoperative recurrent esophageal cancers].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2004 |
[Concurrent chemoradiation using daily low-dose CDDP and UFT-E for postoperative recurrent esophageal cancers].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2004 |
[Concurrent chemoradiation using daily low-dose CDDP and UFT-E for postoperative recurrent esophageal cancers].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2004 |
[Concurrent chemoradiation using daily low-dose CDDP and UFT-E for postoperative recurrent esophageal cancers].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2004 |
[Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 2005 |
[Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 2005 |
[Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 2005 |
[Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 2005 |
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
34 trials available for tegafur and Esophageal Neoplasms
| Article | Year |
|---|---|
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esop | 2020 |
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esop | 2020 |
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esop | 2020 |
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esop | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; | 2017 |
S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; | 2017 |
S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; | 2017 |
S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; | 2017 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2019 |
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2019 |
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2019 |
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2013 |
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Sur | 2014 |
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Sur | 2014 |
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Sur | 2014 |
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Sur | 2014 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Es | 2014 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Es | 2014 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Es | 2014 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Es | 2014 |
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2015 |
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2015 |
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2015 |
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2015 |
A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JC
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2015 |
A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JC
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2015 |
A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JC
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2015 |
A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JC
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2015 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com | 2016 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com | 2016 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com | 2016 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com | 2016 |
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Drug Combinations; | 2008 |
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Drug Combinations; | 2008 |
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Drug Combinations; | 2008 |
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Drug Combinations; | 2008 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Res | 2011 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Res | 2011 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Res | 2011 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Res | 2011 |
Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cytokines; Drug Therapy, Combination; Esophageal Neop | 2012 |
Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cytokines; Drug Therapy, Combination; Esophageal Neop | 2012 |
Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cytokines; Drug Therapy, Combination; Esophageal Neop | 2012 |
Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cytokines; Drug Therapy, Combination; Esophageal Neop | 2012 |
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2005 |
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2005 |
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2005 |
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2005 |
[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2006 |
[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2006 |
[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2006 |
[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2008 |
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2008 |
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2008 |
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2008 |
[Multidisciplinary therapy for esophageal carcinoma. Cooperative Study Group for Esophageal Carcinoma].
Topics: Alcohol Drinking; Bleomycin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; | 1984 |
[Multidisciplinary therapy for esophageal carcinoma. Cooperative Study Group for Esophageal Carcinoma].
Topics: Alcohol Drinking; Bleomycin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; | 1984 |
[Multidisciplinary therapy for esophageal carcinoma. Cooperative Study Group for Esophageal Carcinoma].
Topics: Alcohol Drinking; Bleomycin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; | 1984 |
[Multidisciplinary therapy for esophageal carcinoma. Cooperative Study Group for Esophageal Carcinoma].
Topics: Alcohol Drinking; Bleomycin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; | 1984 |
Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy | 1999 |
Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy | 1999 |
Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy | 1999 |
Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy | 1999 |
[Clinical trial of UFT in malignancies--an analysis of 337 patients. Co-operative Group for Clinical Study of UFT].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1986 |
[Clinical trial of UFT in malignancies--an analysis of 337 patients. Co-operative Group for Clinical Study of UFT].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1986 |
[Clinical trial of UFT in malignancies--an analysis of 337 patients. Co-operative Group for Clinical Study of UFT].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1986 |
[Clinical trial of UFT in malignancies--an analysis of 337 patients. Co-operative Group for Clinical Study of UFT].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1986 |
100 other studies available for tegafur and Esophageal Neoplasms
| Article | Year |
|---|---|
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm | 2021 |
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm | 2021 |
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm | 2021 |
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm | 2021 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dr | 2019 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dr | 2019 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dr | 2019 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dr | 2019 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2021 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2021 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2021 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2021 |
[Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 2017 |
[Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 2017 |
[Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 2017 |
[Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 2017 |
[A Case of Advanced Esophagogastric Junction Cancer Responding to S-1 Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Esophagoga | 2018 |
[A Case of Advanced Esophagogastric Junction Cancer Responding to S-1 Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Esophagoga | 2018 |
[A Case of Advanced Esophagogastric Junction Cancer Responding to S-1 Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Esophagoga | 2018 |
[A Case of Advanced Esophagogastric Junction Cancer Responding to S-1 Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Esophagoga | 2018 |
S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2019 |
S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2019 |
S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2019 |
S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
[A case of esophageal cancer with a funnel chest].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; E | 2013 |
[A case of esophageal cancer with a funnel chest].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; E | 2013 |
[A case of esophageal cancer with a funnel chest].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; E | 2013 |
[A case of esophageal cancer with a funnel chest].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; E | 2013 |
Preoperative chemoradiation therapy decreases the number of lymph nodes resected during esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Preoperative chemoradiation therapy decreases the number of lymph nodes resected during esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Preoperative chemoradiation therapy decreases the number of lymph nodes resected during esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Preoperative chemoradiation therapy decreases the number of lymph nodes resected during esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 2016 |
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 2016 |
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 2016 |
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 2016 |
[Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Eso | 2014 |
[Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Eso | 2014 |
[Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Eso | 2014 |
[Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Eso | 2014 |
[A case of AFP-producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Es | 2014 |
[A case of AFP-producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Es | 2014 |
[A case of AFP-producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Es | 2014 |
[A case of AFP-producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Es | 2014 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 2016 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 2016 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 2016 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 2016 |
[A Case of Carcinosarcoma of the Esophagus Treated with Chemoradiotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinosarcoma; Chemoradiotherapy; Drug Combinat | 2015 |
[A Case of Carcinosarcoma of the Esophagus Treated with Chemoradiotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinosarcoma; Chemoradiotherapy; Drug Combinat | 2015 |
[A Case of Carcinosarcoma of the Esophagus Treated with Chemoradiotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinosarcoma; Chemoradiotherapy; Drug Combinat | 2015 |
[A Case of Carcinosarcoma of the Esophagus Treated with Chemoradiotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinosarcoma; Chemoradiotherapy; Drug Combinat | 2015 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2016 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2016 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2016 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cispla | 2017 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cispla | 2017 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cispla | 2017 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cispla | 2017 |
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Esophag | 2016 |
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Esophag | 2016 |
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Esophag | 2016 |
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Esophag | 2016 |
[A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Esoph | 2016 |
[A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Esoph | 2016 |
[A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Esoph | 2016 |
[A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Esoph | 2016 |
[Case of esophageal cancer successfully performed in early response evaluation for preoperative chemotherapy by FDG-PET].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
[Case of esophageal cancer successfully performed in early response evaluation for preoperative chemotherapy by FDG-PET].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
[Case of esophageal cancer successfully performed in early response evaluation for preoperative chemotherapy by FDG-PET].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
[Case of esophageal cancer successfully performed in early response evaluation for preoperative chemotherapy by FDG-PET].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
[Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combination | 2009 |
[Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combination | 2009 |
[Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combination | 2009 |
[Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combination | 2009 |
[Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Electrocardiogr | 2009 |
[Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Electrocardiogr | 2009 |
[Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Electrocardiogr | 2009 |
[Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Electrocardiogr | 2009 |
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
[Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Combined | 2010 |
[Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Combined | 2010 |
[Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Combined | 2010 |
[Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Combined | 2010 |
A complete response in small cell carcinoma of the esophagus treated by s-1/cisplatin combined chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthma; Carcinoma, Small Cell; Cisplatin; Comb | 2010 |
A complete response in small cell carcinoma of the esophagus treated by s-1/cisplatin combined chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthma; Carcinoma, Small Cell; Cisplatin; Comb | 2010 |
A complete response in small cell carcinoma of the esophagus treated by s-1/cisplatin combined chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthma; Carcinoma, Small Cell; Cisplatin; Comb | 2010 |
A complete response in small cell carcinoma of the esophagus treated by s-1/cisplatin combined chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthma; Carcinoma, Small Cell; Cisplatin; Comb | 2010 |
[A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
Topics: Aged; Antineoplastic Agents; Cardia; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagosco | 2008 |
[A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
Topics: Aged; Antineoplastic Agents; Cardia; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagosco | 2008 |
[A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
Topics: Aged; Antineoplastic Agents; Cardia; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagosco | 2008 |
[A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
Topics: Aged; Antineoplastic Agents; Cardia; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagosco | 2008 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; | 2010 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; | 2010 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; | 2010 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; | 2010 |
[Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; | 2010 |
[Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; | 2010 |
[Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; | 2010 |
[Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; | 2010 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combina | 2011 |
A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combina | 2011 |
A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combina | 2011 |
A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combina | 2011 |
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2011 |
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2011 |
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2011 |
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2011 |
[A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2011 |
[A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2011 |
[A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2011 |
[A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2011 |
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinat | 2011 |
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinat | 2011 |
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinat | 2011 |
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinat | 2011 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophagea | 2012 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophagea | 2012 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophagea | 2012 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophagea | 2012 |
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cisplatin; Disease Progression; Drug Combinat | 2012 |
A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cisplatin; Disease Progression; Drug Combinat | 2012 |
A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cisplatin; Disease Progression; Drug Combinat | 2012 |
A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cisplatin; Disease Progression; Drug Combinat | 2012 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes | 2012 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes | 2012 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes | 2012 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes | 2012 |
[A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2012 |
[A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2012 |
[A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2012 |
[A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2012 |
[A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Gastrectom | 2002 |
[A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Gastrectom | 2002 |
[A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Gastrectom | 2002 |
[A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Gastrectom | 2002 |
[A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2002 |
[A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2002 |
[A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2002 |
[A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2002 |
[A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Combined Modalit | 2003 |
[A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Combined Modalit | 2003 |
[A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Combined Modalit | 2003 |
[A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Combined Modalit | 2003 |
[Remarkable response of simultaneous advanced esophageal and gastric cancer to combined chemotherapy with weekday-on/Weekend-off TS-1 plus biweekly cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Carcinoma, Squamo | 2003 |
[Remarkable response of simultaneous advanced esophageal and gastric cancer to combined chemotherapy with weekday-on/Weekend-off TS-1 plus biweekly cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Carcinoma, Squamo | 2003 |
[Remarkable response of simultaneous advanced esophageal and gastric cancer to combined chemotherapy with weekday-on/Weekend-off TS-1 plus biweekly cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Carcinoma, Squamo | 2003 |
[Remarkable response of simultaneous advanced esophageal and gastric cancer to combined chemotherapy with weekday-on/Weekend-off TS-1 plus biweekly cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Carcinoma, Squamo | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration S | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration S | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration S | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration S | 2003 |
[Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2004 |
[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2004 |
[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2004 |
[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2004 |
[A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient].
Topics: Aged; Antimetabolites, Antineoplastic; Barrett Esophagus; Drug Administration Schedule; Drug Combina | 2004 |
[A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient].
Topics: Aged; Antimetabolites, Antineoplastic; Barrett Esophagus; Drug Administration Schedule; Drug Combina | 2004 |
[A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient].
Topics: Aged; Antimetabolites, Antineoplastic; Barrett Esophagus; Drug Administration Schedule; Drug Combina | 2004 |
[A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient].
Topics: Aged; Antimetabolites, Antineoplastic; Barrett Esophagus; Drug Administration Schedule; Drug Combina | 2004 |
[A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 2004 |
[A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 2004 |
[A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 2004 |
[A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 2004 |
[A case of advanced cervical and upper thoracic esophageal carcinoma completely responding to chemoradiotherapy with TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
[A case of advanced cervical and upper thoracic esophageal carcinoma completely responding to chemoradiotherapy with TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
[A case of advanced cervical and upper thoracic esophageal carcinoma completely responding to chemoradiotherapy with TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
[A case of advanced cervical and upper thoracic esophageal carcinoma completely responding to chemoradiotherapy with TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
[A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2004 |
[A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2004 |
[A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2004 |
[A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2004 |
[Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2005 |
[Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2005 |
[Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2005 |
[Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2005 |
[A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy].
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2006 |
[A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy].
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2006 |
[A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy].
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2006 |
[A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy].
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2006 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Dr | 2006 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Dr | 2006 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Dr | 2006 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Dr | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
[A case of advanced esophageal cancer with suspected tracheoesophageal fistula that responded to chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2006 |
[A case of advanced esophageal cancer with suspected tracheoesophageal fistula that responded to chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2006 |
[A case of advanced esophageal cancer with suspected tracheoesophageal fistula that responded to chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2006 |
[A case of advanced esophageal cancer with suspected tracheoesophageal fistula that responded to chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
[Complete response in a case of advanced esophageal and gastric double cancer treated by chemotherapy of TS-1 and low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2006 |
[Complete response in a case of advanced esophageal and gastric double cancer treated by chemotherapy of TS-1 and low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2006 |
[Complete response in a case of advanced esophageal and gastric double cancer treated by chemotherapy of TS-1 and low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2006 |
[Complete response in a case of advanced esophageal and gastric double cancer treated by chemotherapy of TS-1 and low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2006 |
[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Ther | 2007 |
[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Ther | 2007 |
[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Ther | 2007 |
[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Ther | 2007 |
Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Drug C | 2007 |
Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Drug C | 2007 |
Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Drug C | 2007 |
Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Drug C | 2007 |
Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2007 |
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2007 |
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2007 |
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2007 |
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2007 |
[S-1 chemotherapy for cancer of the gastric tube used for esophageal reconstruction following surgery for esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Combinations; Esophage | 2007 |
[S-1 chemotherapy for cancer of the gastric tube used for esophageal reconstruction following surgery for esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Combinations; Esophage | 2007 |
[S-1 chemotherapy for cancer of the gastric tube used for esophageal reconstruction following surgery for esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Combinations; Esophage | 2007 |
[S-1 chemotherapy for cancer of the gastric tube used for esophageal reconstruction following surgery for esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Combinations; Esophage | 2007 |
[Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2007 |
[Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2007 |
[Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2007 |
[Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2007 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal | 2008 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal | 2008 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal | 2008 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal | 2008 |
Adjuvant long-term immunochemotherapy for squamous cell carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Immunotherap | 1980 |
Adjuvant long-term immunochemotherapy for squamous cell carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Immunotherap | 1980 |
Adjuvant long-term immunochemotherapy for squamous cell carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Immunotherap | 1980 |
Adjuvant long-term immunochemotherapy for squamous cell carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Immunotherap | 1980 |
Postoperative long-term immunochemotherapy for esophageal carcinoma. 5 year survival.
Topics: Adjuvants, Immunologic; Adult; Aged; BCG Vaccine; Bleomycin; Carcinoma, Squamous Cell; Esophageal Ne | 1982 |
Postoperative long-term immunochemotherapy for esophageal carcinoma. 5 year survival.
Topics: Adjuvants, Immunologic; Adult; Aged; BCG Vaccine; Bleomycin; Carcinoma, Squamous Cell; Esophageal Ne | 1982 |
Postoperative long-term immunochemotherapy for esophageal carcinoma. 5 year survival.
Topics: Adjuvants, Immunologic; Adult; Aged; BCG Vaccine; Bleomycin; Carcinoma, Squamous Cell; Esophageal Ne | 1982 |
Postoperative long-term immunochemotherapy for esophageal carcinoma. 5 year survival.
Topics: Adjuvants, Immunologic; Adult; Aged; BCG Vaccine; Bleomycin; Carcinoma, Squamous Cell; Esophageal Ne | 1982 |
Multidisciplinary treatment for esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Bleomycin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1983 |
Multidisciplinary treatment for esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Bleomycin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1983 |
Multidisciplinary treatment for esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Bleomycin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1983 |
Multidisciplinary treatment for esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Bleomycin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1983 |
[Effect of preoperative adjuvant therapy of esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Esophageal Neo | 1984 |
[Effect of preoperative adjuvant therapy of esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Esophageal Neo | 1984 |
[Effect of preoperative adjuvant therapy of esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Esophageal Neo | 1984 |
[Effect of preoperative adjuvant therapy of esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Esophageal Neo | 1984 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
[A case of inoperable esophageal carcinoma responding to adriamycin and FT 207 suppository for more than one year (author's transl)].
Topics: Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal Neoplasms; Female | 1981 |
[A case of inoperable esophageal carcinoma responding to adriamycin and FT 207 suppository for more than one year (author's transl)].
Topics: Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal Neoplasms; Female | 1981 |
[A case of inoperable esophageal carcinoma responding to adriamycin and FT 207 suppository for more than one year (author's transl)].
Topics: Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal Neoplasms; Female | 1981 |
[A case of inoperable esophageal carcinoma responding to adriamycin and FT 207 suppository for more than one year (author's transl)].
Topics: Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal Neoplasms; Female | 1981 |
[Light and electron microscopic examination compared to evaluation by tumor size in subrenal capsule assay for chemosensitivity testing in esophageal cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esopha | 1995 |
[Light and electron microscopic examination compared to evaluation by tumor size in subrenal capsule assay for chemosensitivity testing in esophageal cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esopha | 1995 |
[Light and electron microscopic examination compared to evaluation by tumor size in subrenal capsule assay for chemosensitivity testing in esophageal cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esopha | 1995 |
[Light and electron microscopic examination compared to evaluation by tumor size in subrenal capsule assay for chemosensitivity testing in esophageal cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esopha | 1995 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
Combination chemotherapy for a senile patient with adenoid cystic carcinoma of the esophagus: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Esophageal Neoplasm | 1993 |
Combination chemotherapy for a senile patient with adenoid cystic carcinoma of the esophagus: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Esophageal Neoplasm | 1993 |
Combination chemotherapy for a senile patient with adenoid cystic carcinoma of the esophagus: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Esophageal Neoplasm | 1993 |
Combination chemotherapy for a senile patient with adenoid cystic carcinoma of the esophagus: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Esophageal Neoplasm | 1993 |
[Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1996 |
[Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1996 |
[Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1996 |
[Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1996 |
[A case of esophageal cancer with excellent response to oral UFT treatment].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug | 1999 |
[A case of esophageal cancer with excellent response to oral UFT treatment].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug | 1999 |
[A case of esophageal cancer with excellent response to oral UFT treatment].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug | 1999 |
[A case of esophageal cancer with excellent response to oral UFT treatment].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug | 1999 |
Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
[Effective and low toxicity chemoradiotherapy for distant metastatic esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
[Effective and low toxicity chemoradiotherapy for distant metastatic esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
[Effective and low toxicity chemoradiotherapy for distant metastatic esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
[Effective and low toxicity chemoradiotherapy for distant metastatic esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
[Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2002 |
[Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2002 |
[Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2002 |
[Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2002 |
[A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug | 2002 |
[A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug | 2002 |
[A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug | 2002 |
[A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug | 2002 |
[Combined radio-chemotherapy of progressive esophageal cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 1992 |
[Combined radio-chemotherapy of progressive esophageal cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 1992 |
[Combined radio-chemotherapy of progressive esophageal cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 1992 |
[Combined radio-chemotherapy of progressive esophageal cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 1992 |
[A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Floxurid | 1992 |
[A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Floxurid | 1992 |
[A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Floxurid | 1992 |
[A case of recurrent esophageal cancer maintaining complete long-term response after 5'-DFUR and ftorafur administrations].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Floxurid | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
[A case of complete remission of lymph nodes metastasis from esophageal cancer with combination treatment of UFT and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1992 |
[A case of complete remission of lymph nodes metastasis from esophageal cancer with combination treatment of UFT and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1992 |
[A case of complete remission of lymph nodes metastasis from esophageal cancer with combination treatment of UFT and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1992 |
[A case of complete remission of lymph nodes metastasis from esophageal cancer with combination treatment of UFT and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1992 |
[Regional immunochemotherapy for liver metastasis of esophageal cancer in a patient with variant hepatic artery].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1991 |
[Regional immunochemotherapy for liver metastasis of esophageal cancer in a patient with variant hepatic artery].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1991 |
[Regional immunochemotherapy for liver metastasis of esophageal cancer in a patient with variant hepatic artery].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1991 |
[Regional immunochemotherapy for liver metastasis of esophageal cancer in a patient with variant hepatic artery].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1991 |
[Multidisciplinary treatment of esophageal cancer].
Topics: Adult; Aged; Bleomycin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; | 1985 |
[Multidisciplinary treatment of esophageal cancer].
Topics: Adult; Aged; Bleomycin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; | 1985 |
[Multidisciplinary treatment of esophageal cancer].
Topics: Adult; Aged; Bleomycin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; | 1985 |
[Multidisciplinary treatment of esophageal cancer].
Topics: Adult; Aged; Bleomycin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; | 1985 |
[COPU regimen in the treatment of 35 esophageal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 1989 |
[COPU regimen in the treatment of 35 esophageal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 1989 |
[COPU regimen in the treatment of 35 esophageal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 1989 |
[COPU regimen in the treatment of 35 esophageal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 1989 |
[Current treatment of cancer of the esophagus in our department].
Topics: Combined Modality Therapy; Esophageal Neoplasms; Esophagus; Humans; Neck Dissection; Positive-Pressu | 1986 |
[Current treatment of cancer of the esophagus in our department].
Topics: Combined Modality Therapy; Esophageal Neoplasms; Esophagus; Humans; Neck Dissection; Positive-Pressu | 1986 |
[Current treatment of cancer of the esophagus in our department].
Topics: Combined Modality Therapy; Esophageal Neoplasms; Esophagus; Humans; Neck Dissection; Positive-Pressu | 1986 |
[Current treatment of cancer of the esophagus in our department].
Topics: Combined Modality Therapy; Esophageal Neoplasms; Esophagus; Humans; Neck Dissection; Positive-Pressu | 1986 |
[Experimental study of esophageal cancer--effect of alcohol, vitamin C, prostaglandin E2 and tegafur on carcinogenesis by N-methyl-N-amylnitrosamine and the development of esophageal carcinoma].
Topics: Animals; Ascorbic Acid; Carcinogens; Dinoprostone; Esophageal Neoplasms; Ethanol; Male; Nitrosamines | 1986 |
[Experimental study of esophageal cancer--effect of alcohol, vitamin C, prostaglandin E2 and tegafur on carcinogenesis by N-methyl-N-amylnitrosamine and the development of esophageal carcinoma].
Topics: Animals; Ascorbic Acid; Carcinogens; Dinoprostone; Esophageal Neoplasms; Ethanol; Male; Nitrosamines | 1986 |
[Experimental study of esophageal cancer--effect of alcohol, vitamin C, prostaglandin E2 and tegafur on carcinogenesis by N-methyl-N-amylnitrosamine and the development of esophageal carcinoma].
Topics: Animals; Ascorbic Acid; Carcinogens; Dinoprostone; Esophageal Neoplasms; Ethanol; Male; Nitrosamines | 1986 |
[Experimental study of esophageal cancer--effect of alcohol, vitamin C, prostaglandin E2 and tegafur on carcinogenesis by N-methyl-N-amylnitrosamine and the development of esophageal carcinoma].
Topics: Animals; Ascorbic Acid; Carcinogens; Dinoprostone; Esophageal Neoplasms; Ethanol; Male; Nitrosamines | 1986 |
[Three cases of adenocarcinoma of the lower esophagus and cardia showing marked regression after radiotherapy with FT-207].
Topics: Adenocarcinoma; Aged; Cardia; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; | 1987 |
[Three cases of adenocarcinoma of the lower esophagus and cardia showing marked regression after radiotherapy with FT-207].
Topics: Adenocarcinoma; Aged; Cardia; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; | 1987 |
[Three cases of adenocarcinoma of the lower esophagus and cardia showing marked regression after radiotherapy with FT-207].
Topics: Adenocarcinoma; Aged; Cardia; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; | 1987 |
[Three cases of adenocarcinoma of the lower esophagus and cardia showing marked regression after radiotherapy with FT-207].
Topics: Adenocarcinoma; Aged; Cardia; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; | 1987 |
[UFT in esophageal cancer: a report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms | 1987 |
[UFT in esophageal cancer: a report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms | 1987 |
[UFT in esophageal cancer: a report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms | 1987 |
[UFT in esophageal cancer: a report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms | 1987 |
[Experiences with FT+BrdU+radiation therapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carcinoma, Squamous Cell; C | 1987 |
[Experiences with FT+BrdU+radiation therapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carcinoma, Squamous Cell; C | 1987 |
[Experiences with FT+BrdU+radiation therapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carcinoma, Squamous Cell; C | 1987 |
[Experiences with FT+BrdU+radiation therapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carcinoma, Squamous Cell; C | 1987 |
Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Colonic Neoplasms; | 1988 |
Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Colonic Neoplasms; | 1988 |
Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Colonic Neoplasms; | 1988 |
Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Colonic Neoplasms; | 1988 |